Boston Scientific Corporation has said "yes" to the option of acquiring complete ownership of Millipede, a private company focused on developing the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR).
Having agreed to an investment and acquisition option
back in January 2018, the Massachusetts-based manufacturer acquired $90 million worth of outstanding and newly issued shares, and will now take the remaining ones for an additional $325 million, with a further $125 million to be paid upon the completion of a commercial milestone. Its decision to do so follows the successful completion of a first-in-human clinical trial using the system.
"We are very satisfied with the early results of our clinical program and are excited to see this technology further leveraged by Boston Scientific to expand the mitral repair solutions for patients around the world," said Randy Lashinski, co-founder and CEO of Millipede, in a statement.
Estimated to reach $1 billion by 2021, the majority of the drive behind the transcatheter mitral repair and replacement market consists of repair procedures.
Administered through a transcatheter-transseptal delivery system, the Millipede IRIS annuloplasty ring can repair and reduce the size of a dilated mitral annulus in standard surgical fashion. It consists of a complete ring that is used as a standalone device, or in combination with other technologies in patients with severe MR, and is highly customizable to a patient’s anatomy and disease state. In addition, the solution is repositionable and retrievable, promoting a high-quality outcome.
The option to acquire the remaining shares was available to Boston Scientific at any time prior to and after the completion of a first-in-human clinical study that met certain parameters. Millipede itself also had the option to compel Boston Scientific to acquire the rest of the shares following the completion of the trial.
The news further builds upon the progress and resources obtained by Boston Scientific over the last year through its many acquisitions which include VENITI
, the privately-held maker of the Vici Venous Stent, for $160 million; Claret Medical
, the producer of the Sentinel Cerebral Embolic Protection System for TAVR operations on patients at risk of stroke; nVision Medical Corporation
, a private enterprise focused on women's health; and Securus Medical Group
, a company that has developed a thermal monitoring system for the continuous measurement of esophageal temperature.
"Upon commercialization, we believe the IRIS system can meet the needs of a currently underserved patient population that requires physiological, less invasive options to treat functional mitral regurgitation in patients with progressive heart failure," said Professor Ian Meredith, executive vice president and global chief medical officer at Boston Scientific. "This device is designed to be highly customizable to a specific patient's mitral anatomy and disease state, and is repositionable and retrievable to promote a high-quality outcome."
The agreement is predicted to close in the first quarter of 2019, with the transaction expected to be dilutive to earnings per share (EPS) for each of the next several years. International trade-offs, though, are anticipated to absorb all dilutive impact, ensuring no net adjusted EPS impact. On a GAAP basis, the deal is expected to be more dilutive for each of the next several years, due to amortization expense and acquisition-related net charges. The agreement is subject to customary closing conditions.
The IRIS Transcatheter Annuloplasty Ring System is an investigational device and is not available for sale.